A simulation study to provide guidance for individuals transitioning from emicizumab to valoctocogene roxaparvovec

Agarwal S¹, Hermans C², Miesbach W³, Pipe S⁴, Sidonio, Jr. R⁵, Osmond D¹, Newman V¹, Henshaw J¹, Peyvandi F⁶

¹BioMarin Pharmaceutical Inc., Novato, CA, USA; ²Division of Adult Haematology, St-Luc University Hospital, Brussels, Belgium; ³Medical Clinic 2, University Hospital, Frankfurt, Germany; ⁴Departments of Pediatrics and Pathology, St-Luc University Hospital, Brussels, Belgium; ³Medical Clinic 2, University Hospital, Frankfurt, Germany; ⁴Departments of Pediatrics and Pathology, St-Luc University Hospital, Brussels, Belgium; ³Medical Clinic 2, University Hospital, Frankfurt, Germany; ⁴Departments of Pediatrics and Pathology, St-Luc University Hospital, Brussels, Belgium; ³Medical Clinic 2, University Hospital, Brussels, Belgium; ³Medical Clinic 2, University Hospital, Brussels, Belgium; ⁴Departments of Pediatrics and Pathology, St-Luc University Hospital, Brussels, Belgium; ⁴Departments, Belgium; ⁴Departments, Belgium; ⁴Departments, Belgium; ⁴Departments, Belgium; ⁴Department, University of Michigan, Ann Arbor, MI, USA; ⁵Hemostasis and Thrombosis at Children's Healthcare of Atlanta at Emory University, Atlanta, GA, USA; ⁶Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy; Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy

Background

- Severe hemophilia A (SHA) is an X-linked recessive bleeding disorder defined by a factor VIII (FVIII) activity level <1 IU/dL¹
- Emicizumab is an antibody mimicking the function of FVIII used for routine prophylaxis in SHA to prevent bleeding²
- Valoctocogene roxaparvovec is a gene therapy for SHA that uses an adeno-associated virus serotype 5 (AAV5) vector to transfer a B-domain-deleted human FVIII-coding sequence that provides improved protection from bleeds compared with FVIII prophylaxis¹
- Valoctocogene roxaparvovec was evaluated in a phase 3, single-arm, open-label study (NCT03370913; GENEr8-1) in 134 participants with SHA who were treated with a single infusion¹
- Most individuals reached therapeutic FVIII activity levels ≥5 IU/dL within 4 to 12 weeks
- At the time of GENEr8-1 initiation, emicizumab was an investigational product, and individuals using it were excluded.¹ Thus, there are limited data available regarding how long to continue emicizumab prophylaxis after receiving valoctocogene roxaparvovec to maintain hemostasis


Aim

8

• To use pharmacokinetic simulations of emicizumab, paired with the FVIII kinetics observed in GENEr8-1, to provide guidance on timing for discontinuation of emicizumab in individuals transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy while maintaining hemostatic control

Theoretical case examples

- To highlight specific considerations that could arise with individuals who are transitioning from emicizumab to valoctocogene roxaparvovec, several theoretical case examples are presented based on actual responses from GENEr8-1 study participants
- All individuals had SHA and no history of inhibitors. FVIII activity was measured weekly with the CSA using bovine reagents



Individual with early FVIII expression by week 4

- A 37-year-old male continued emicizumab 1.5 mg/kg QW for routine prophylaxis after valoctocogene roxaparvovec infusion
- At weeks 4 and 5, his FVIII activity level was 11.8 IU/dL and 12.4 IU/dL, respectively
- Due to FVIII activity levels >5 IU/dL for 2 consecutive weeks, he discontinued emicizumab at week 5
- Twelve weeks after infusion, his FVIII activity levels continued to rise >30 IU/dL, and he remains bleed free

Methods

Emicizumab pharmacokinetic simulations

- A population pharmacokinetic model was published previously that evaluated the pharmacokinetics of emicizumab using a database that included 389 participants with hemophilia A from the HAVEN 1, 2, 3, and 4 clinical trials³
- Three emicizumab dosing regimens were evaluated: 3 mg/kg once weekly (QW) for 4 weeks, as a loading dose, followed by 1.5 mg/kg QW; 3 mg/kg once every 2 weeks (Q2W); and 6 mg/kg once every 4 weeks (Q4W)³
- The mean trough concentration for all 3 dosing regimens is approximately 40 µg/mL³ and hypothesized to correspond with a similar level of hemostatic control as FVIII activity of 10 to 15 IU/dL⁴
- The published model was used to simulate the in vivo, steady-state, emicizumab concentrations presented here. Briefly, 500 replicates of simulated emicizumab concentration-time profiles for 134 participants of GENEr8-1 were conducted for 3 emicizumab dosing regimens (QW, Q2W, and Q4W)

Bleeding risk estimation

- Simulated in vivo emicizumab concentrations were merged with FVIII activity time-course data for each of the 134 participants of GENEr8-1 to calculate the risk of bleeding at weekly intervals for up to 20 weeks after valoctocogene roxaparvovec infusion
- Bleeding risk was based on the assumptions outlined in Table 1


Table 1. Assumptions for the estimation of bleeding risk categories

FVIII activity levels (IU/dL)	Average emicizumab levels at each week (µg/mL)	Bleeding risk category
<5	<15	Greater than emicizumab
	15 to <100	Same as emicizumab
	≥100	Less than emicizumab
5 to <15	<65	Same as emicizumab
	≥65	Less than emicizumab
≥15	Any	Less than emicizumab

Bleeding risk was defined by the emicizumab exposure-response relationship.⁴ If emicizumab concentrations fell below 15 µg/mL and FVIII activity levels were less than 5 IU/dL, then individuals were assumed to have a greater bleeding risk.4,5,6,7 FVIII activity levels >15 IU/dL were assumed to provide hemostatic efficacy. FVIII, factor VIII.


Two scenarios with different timing for discontinuation of emicizumab • Two transition scenarios were evaluated for individuals transitioning from emicizumab to valoctocogene roxaparvovec

The "cautious" approach to continue emicizumab until "goal" FVIII expression was reached



- A 45-year-old male continued emicizumab 1.5 mg/kg QW for routine prophylaxis after valoctocogene roxaparvovec infusion
- At week 4, his FVIII activity level was 11.2 IU/dL and he had 1 traumatic bleed from exercise that was treated with recombinant FVIII. He continued prophylaxis with emicizumab due to his risk of bleeding from regular exercise
- By week 9, he had FVIII activity levels >20 IU/dL for 2 consecutive weeks. However, with his history of bleeds, the individual and his hematologist were cautious about discontinuing emicizumab
- They were reminded that hemostatic efficacy from emicizumab is roughly equivalent to 10 to 15 IU/dL, less than his current FVIII activity level. They agreed to stop emicizumab and continued weekly monitoring of FVIII activity levels
- At week 26, the individual's FVIII activity remained >50 IU/dL, and he did not have any additional spontaneous bleeds

Individual who never achieved adequate FVIII activity levels by 12 weeks post dosing



- A 53-year-old male continued emicizumab 3 mg/kg Q2W for routine prophylaxis after valoctocogene roxaparvovec infusion
- At week 4, his FVIII activity level was 3.1 IU/dL, and he continued his prophylaxis with emicizumab since his FVIII activity level was still <5 IU/dL
- In weeks 8 through 26, his FVIII activity level remained between 3 and 4.8 IU/dL
- He remained on emicizumab 405 mg Q2W for routine prophylaxis due to consistently low FVIII expression after gene therapy

• One year later, this individual remains generally well, and his FVIII activity level at week 52 was 4.6 IU/dL

Individual with FVIII activity levels that appeared adequate by weeks 4 to 8 but declined after transaminitis

- Scenario 1: Last dose of emicizumab on the day of valoctocogene roxaparvovec infusion
- Scenario 2: Last dose of emicizumab occurred 4 weeks after valoctocogene roxaparvovec infusion
- For either transition scenario, emicizumab levels would have declined by greater than 90% by the end of the presented modeling experiments


Results

Estimation of bleeding risk


- Early discontinuation of emicizumab with the last dose on the day of valoctocogene roxaparvovec infusion (scenario 1) vs additional doses of emicizumab for up to 4 weeks (scenario 2) offered similar levels of hemostatic control (Figure 1)
- Bleeding risk was also comparable across the 3 emicizumab dosing regimens for both scenarios

Figure 1. Proportion of individuals with bleeding risk over time

Less than emicizumab Greater than emicizumab Same as emicizumab 100 75 viduals 50 25 15 20 10 Scenario 2: Last emicizumab dose on week 4 after valoctocogene roxaparvovec infusion Greater than emicizumab Less than emicizumab Same as emicizumab 100 -75 50 25 -



- A 26-year-old male continued emicizumab 1.5 mg/kg QW for routine prophylaxis after valoctocogene roxaparvovec infusion
 - At weeks 4 and 5, his FVIII activity levels were 9.7 IU/dL and 12.2 IU/dL, respectively, and so he discontinued emicizumab
 - At week 7, FVIII activity continued to rise but his alanine aminotransferase (ALT) increased to 52 U/L, which was greater than 2 times his ALT prior to valoctocogene roxaparvovec infusion
- During his week 8 assessment, his ALT remained elevated, and his FVIII activity level declined. Prednisone 60 mg was initiated. Subsequently, ALT levels returned to normal, and his FVIII activity levels began to rise again • At week 12, his FVIII activity was 40.1 IU/dL. He continued to remain off emicizumab for prophylaxis due to continued hemostatic control after valoctocogene roxaparvovec infusion



Individual with high FVIII levels

- A 33-year-old male continued his regular schedule of emicizumab 6 mg/kg Q4W after valoctocogene roxaparvovec infusion
- At week 7, his FVIII activity level was 40.5 IU/dL, and he discontinued emicizumab the following week
- His FVIII activity level continued to rise and at week 17 it was greater than the upper limit of normal (ULN) at 161 IU/dL. His ALT levels remained normal
- Based on his hematologist's assessment, there were no risk factors for thromboembolic events and thus no anticoagulation or antiplatelet therapy was administered. Within 3 weeks, his FVIII activity level returned to within normal ranges, and no adverse events were reported
- He has remained off emicizumab for prophylaxis due to continued hemostatic control after valoctocogene roxaparvovec infusion

Scenario 1: Last emicizumab dose on same day as valoctocogene roxaparvovec infusion

Time following valoctocogene roxaparvovec infusion (weeks)


Regimen -QW - Q2W - Q4W

FVIII, factor VIII; Q2W, once every 2 weeks; Q4W, once every 4 weeks; QW, once weekly.

Timing of discontinuation of emicizumab after gene therapy

- An algorithm to guide decisions around when emicizumab can be discontinued was developed based on the results of the simulations to estimate bleeding risk (Figure 2)
- The chromogenic substrate assay (CSA) using bovine reagents must be used to monitor endogenous FVIII activity in those receiving emicizumab
- The interaction between emicizumab and human factor IXa and factor X yields artificially high results⁸

Figure 2. Treatment algorithm for discontinuation of emicizumab when transitioning to valoctocogene roxaparvovec



^aPrescribers should consider continuing emicizumab prophylaxis and continue weekly monitoring of FVIII activity levels until 2 consecutive weekly measurements ≥5 IU/dL are achieved before discontinuation of emicizumab. FVIII, factor VIII; Q4W, once every 4 weeks.

Discussion

- Pharmacokinetic simulations showed no meaningful difference in the risk of bleeding while transitioning to valoctocogene roxaparvovec treatment following different emicizumab discontinuation times and dosing regimens
- The bleeding risk is determined by the dynamic balance of decaying emicizumab levels and increasing gene therapy-derived endogenous FVIII
- These original data suggest individuals on emicizumab prophylaxis can safely transition to valoctocogene roxaparvovec using multiple approaches

Acknowledgements

We thank Tara Robinson of BioMarin Pharmaceutical Inc., for her contribution to this study. Funding for this study was provided by BioMarin Pharmaceutical Inc. Medical writing support was provided by Tony Sallese, PhD, of AlphaBioCom, a Red Nucleus company, and funded by BioMarin Pharmaceutical Inc.

Disclosures

CH reports consulting fees and honoraria as a speaker for educational symposia for Shire, Pfizer, Bayer, Octapharma, LFB, CAF-DCF, Roche, Novo Nordisk, CSL Behring, Sobi, Bioverativ, and Kedrion. WM reports grant and research support from Bayer, Biotest, CSL, LFB, Novo Nordisk, Octapharma, Pfizer, Sobi, Takeda, and UniQure; received consulting fees from BioMarin Pharmaceutical Inc., Freeline, LFB, Octapharma, Sobi, Novartis, Novo Nordisk, Pfizer, and Roche; and reports honoraria as a speaker for educational symposia for Shire, Pfizer, Bayer, Sobi, Amgen, Novartis, Alexion, LEO Pharma, Grifols, Roche, and Novo Nordisk. FP reports honoraria as a speaker for educational symposia by Grifols, Sanofi, and Takeda and as an advisory member for Sanofi and Roche. RS reports grants and consulting fees from Bayer, Genentech, Hema Biologics, Novo Nordisk, BioMarin Pharmaceutical Inc., Octapharma, Pfizer, Roche, Sanofi, Sigilon, Sobi, Guardian Therapeutics, and Takeda. SWP reports consulting fees from Apcintex, ASC Therapeutics, Bayer, BioMarin Pharmaceutical Inc., CSL Behring, HEMA Biologics, Freeline, Novo Nordisk, Pfizer, Roche/Genentech, Sanofi, Spark Therapeutics, Takeda, and uniQure; and service as a clinical trial investigator for BioMarin Pharmaceutical Inc., Freeline, Genentech/Roche, Sanofi, and uniQure. SA, DO, and JH are employees and stockholders of BioMarin Pharmaceutical Inc. VN is a former employee of BioMarin Pharmaceutical Inc.

References

1. Ozelo M, et al. N Engl J Med. 2022;386(11):1013-25. 2. Srivastava A, et al. Haemophilia. 2020;26(suppl 6):1-158. 3. Retout S, et al. Clin Pharmacokinet. 2020; 59(12):1611-25. 4. Shima M, et al. N Engl J Med. 2016;374(21):2044-53. 5. Lehtinen P, et al. Haemophilia. 2022;28(2):53-5. 6. Tang A, et al. Res Pract Thromb Haemost. 2021;5(Suppl 2). 7. Jonsson F, et al. Clin Pharmacokinet. 2021;60(7):931-41. 8. Adamkewicz J, et al. *Thromb Haemost.* 2019;119(7):1084-93.